IL172762A0 - Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor - Google Patents

Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Info

Publication number
IL172762A0
IL172762A0 IL172762A IL17276205A IL172762A0 IL 172762 A0 IL172762 A0 IL 172762A0 IL 172762 A IL172762 A IL 172762A IL 17276205 A IL17276205 A IL 17276205A IL 172762 A0 IL172762 A0 IL 172762A0
Authority
IL
Israel
Prior art keywords
octan
oxazolidin
azabicyclo
spiro
affinity
Prior art date
Application number
IL172762A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Chang Hui Fang
Phillips Eilion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Chang Hui Fang, Phillips Eilion filed Critical Astrazeneca Ab
Publication of IL172762A0 publication Critical patent/IL172762A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL172762A 2003-07-08 2005-12-22 Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor IL172762A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48552303P 2003-07-08 2003-07-08
PCT/GB2004/002904 WO2005005435A1 (en) 2003-07-08 2004-07-06 Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Publications (1)

Publication Number Publication Date
IL172762A0 true IL172762A0 (en) 2006-04-10

Family

ID=34062082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172762A IL172762A0 (en) 2003-07-08 2005-12-22 Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Country Status (17)

Country Link
US (1) US7514567B2 (https=)
EP (1) EP1654264A1 (https=)
JP (1) JP2007516200A (https=)
KR (1) KR20060057569A (https=)
CN (1) CN1829721A (https=)
AR (1) AR045040A1 (https=)
AU (1) AU2004255920B2 (https=)
BR (1) BRPI0412382A (https=)
CA (1) CA2531510A1 (https=)
IL (1) IL172762A0 (https=)
MX (1) MXPA06000231A (https=)
NO (1) NO20060612L (https=)
NZ (1) NZ545132A (https=)
SA (1) SA04250212B1 (https=)
TW (1) TW200524942A (https=)
WO (1) WO2005005435A1 (https=)
ZA (1) ZA200600154B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006743A (es) * 2004-12-15 2007-07-09 Astrazeneca Ab Ligandos del receptor de acetilcolina nicotinica.
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US20100105685A1 (en) * 2006-10-03 2010-04-29 Galleon Pharmaceuticals, Inc. S-Nitrosothiol Compounds and Related Derivatives
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2583556B1 (de) * 2008-07-17 2016-01-20 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UA107791C2 (en) * 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US8759550B2 (en) 2009-08-27 2014-06-24 Yeda Research And Development Co. Ltd. Oligo- and polyfurans, preparation and uses thereof
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2011056573A1 (en) 2009-10-28 2011-05-12 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2558458B1 (de) 2010-04-16 2017-09-06 Bayer Intellectual Property GmbH Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
MA34462B1 (fr) 2010-07-22 2013-08-01 Novartis Ag Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TWI703133B (zh) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 3,5-二胺基吡唑激酶抑制劑
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
ATE192157T1 (de) * 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
AU2001241056A1 (en) * 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs

Also Published As

Publication number Publication date
NZ545132A (en) 2009-07-31
CA2531510A1 (en) 2005-01-20
NO20060612L (no) 2006-04-06
AR045040A1 (es) 2005-10-12
AU2004255920A1 (en) 2005-01-20
JP2007516200A (ja) 2007-06-21
US20060154945A1 (en) 2006-07-13
SA04250212B1 (ar) 2009-08-11
EP1654264A1 (en) 2006-05-10
CN1829721A (zh) 2006-09-06
TW200524942A (en) 2005-08-01
US7514567B2 (en) 2009-04-07
AU2004255920B2 (en) 2008-05-15
ZA200600154B (en) 2007-04-25
KR20060057569A (ko) 2006-05-26
MXPA06000231A (es) 2006-04-11
WO2005005435A1 (en) 2005-01-20
BRPI0412382A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
IL172762A0 (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
AU2003212296A1 (en) Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
IL225968A0 (en) 1- Aza-bicyclo [3.3.1] nonanes
SI1725567T1 (sl) Spirociklični cikloheksanski derivati z afiniteto za ORL1 receptor
AP2213A (en) Muscarinic acetylcholine receptor antagonists.
AP1828A (en) Muscarinic Acetycholine receptor antagonists
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
AU3809999A (en) Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
IL186354A0 (en) INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF TRANS -5-CHLORO-2-METHYL-2,3,3a,12b-TETRAHYDRO-1H -DIBENZ[2,3:6,7] OXEPINO [4,5-c] PYRROLE
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
IL178241A0 (en) NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
DE69915603D1 (de) Imidazo[1,2-a]pyridine als mittel zum binden des peripheralen benzodiazepin-rezeptors
AP2006003478A0 (en) Muscarinic acetylcholine receptor antagonists.
AP2006003575A0 (en) Muscarinic acetylcholine receptor antagonists.
TR199901381A3 (tr) Diaza-spiro[3,5]nonan türevleri.
AU2003202727A1 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ZA200803821B (en) Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
EP1545508A4 (en) 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
HK1089162A (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
ZA991411B (en) Substituted imidazo [1,2-A:3,4A']diquinolinylium interleukin-8 receptor antagonist.